# Minimum Effective Dose of Incisional Local Infiltration Betamethasone for the Prevention of Pain After Spinal Surgery

> **NCT06785350** · NA · RECRUITING · sponsor: **Beijing Tiantan Hospital** · enrollment: 535 (estimated)

## Conditions studied

- Pain Management
- Spine Surgery

## Interventions

- **DRUG:** 0.012%diprospan+0.5%ropivacaine
- **DRUG:** 0.009%diprospan+0.5%ropivacaine
- **DRUG:** 0.006%diprospan+0.5ropivacaine
- **DRUG:** 0.003%diprospan+0.5%ropivacaine
- **DRUG:** 0.5%ropivacaine

## Key facts

- **NCT ID:** NCT06785350
- **Lead sponsor:** Beijing Tiantan Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-25
- **Primary completion:** 2025-09-01
- **Final completion:** 2025-12-01
- **Target enrollment:** 535 (ESTIMATED)
- **Last updated:** 2025-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06785350

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06785350, "Minimum Effective Dose of Incisional Local Infiltration Betamethasone for the Prevention of Pain After Spinal Surgery". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06785350. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*